| 1 |
35045360 | Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. | 2022 Mar-Apr |
4 |
| 2 |
34428101 | Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. | 2021 Sep |
1 |
| 3 |
32502444 | Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. | 2020 Jun |
1 |
| 4 |
32817132 | Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). | 2020 Aug |
1 |
| 5 |
30685073 | Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. | 2019 Feb |
1 |
| 6 |
31092758 | [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma]. | 2019 |
1 |
| 7 |
29433850 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | 2018 Mar 24 |
1 |
| 8 |
29468981 | Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. | 2018 |
2 |
| 9 |
29515414 | A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. | 2018 Jan-Apr |
1 |
| 10 |
29517103 | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. | 2018 May |
2 |
| 11 |
29656442 | Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). | 2018 Jun 1 |
1 |
| 12 |
30032643 | Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. | 2018 Jan-Dec |
1 |
| 13 |
30069768 | Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. | 2018 |
1 |
| 14 |
30220234 | Lenvatinib as a therapy for unresectable hepatocellular carcinoma. | 2018 Nov |
1 |
| 15 |
27704266 | Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. | 2017 Apr |
1 |
| 16 |
28236116 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor. | 2017 Dec |
1 |
| 17 |
31093354 | Optimal use of lenvatinib in the treatment of advanced thyroid cancer. | 2017 |
1 |
| 18 |
26500236 | Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. | 2016 Mar 15 |
1 |
| 19 |
26678514 | Lenvatinib: Role in thyroid cancer and other solid tumors. | 2016 Jan |
1 |
| 20 |
26867945 | Lenvatinib: A Review in Refractory Thyroid Cancer. | 2016 Feb |
2 |
| 21 |
27339111 | Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. | 2016 Oct |
1 |
| 22 |
27817859 | [Lenvatinib in radioiodine refractory thyroid carcinomas]. | 2016 Nov |
1 |
| 23 |
25795101 | Lenvatinib: first global approval. | 2015 Apr |
2 |
| 24 |
26075440 | Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer? | 2015 |
2 |
| 25 |
24190702 | A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). | 2014 Jan |
1 |
| 26 |
25197551 | Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. | 2014 |
1 |
| 27 |
25295214 | Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. | 2014 |
1 |